C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
2.530
-0.120 (-4.53%)
At close: Nov 17, 2026, 4:00 PM EST
2.520
-0.010 (-0.40%)
After-hours: Nov 17, 2026, 7:41 PM EST

C4 Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
3321852542782891,566
Market Cap Growth
38.79%-27.16%-8.73%-3.60%-81.55%9.83%
Enterprise Value
1134737104111,108
Last Close Price
2.521.913.605.655.9032.20

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
10.275.157.1413.429.2934.20
PB Ratio
1.450.721.181.131.004.02
P/TBV Ratio
1.450.721.181.131.004.02

EV Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EV/Sales Ratio
3.471.301.035.020.3524.20

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
0.240.230.300.290.300.11
Net Debt / Equity Ratio
-0.96-0.92-0.93-0.86-0.86-1.05
Net Debt / EBITDA Ratio
2.182.311.751.541.965.07
Net Debt / FCF Ratio
2.752.393.081.942.244.63
Asset Turnover
0.110.100.100.050.070.10
Quick Ratio
4.997.605.496.216.236.15
Current Ratio
5.177.815.716.346.466.36
Return on Equity (ROE)
-47.62%-44.44%-45.58%-49.50%-37.76%-25.03%
Return on Assets (ROA)
-21.34%-18.43%-20.17%-21.53%-17.27%-11.32%
Return on Capital Employed (ROCE)
-35.10%-32.00%-38.50%-41.70%-33.50%-18.00%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-28.23%-56.72%-41.44%-47.58%-44.38%-5.36%
FCF Yield
-24.05%-53.64%-25.71%-38.98%-38.58%-5.64%
Buyback Yield / Dilution
-78.97%-19.49%-39.75%-1.59%-6.13%-304.93%
SEC Filings: 10-K · 10-Q